MedTrace Logo

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma

NCT06461182 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-06-14

No results posted yet for this study

Summary

This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.

Conditions

  • Indolent B-Cell Non-Hodgkin Lymphoma

Interventions

DRUG

Ga-68-CXCR4

Ga-68-CXCR4 for PET/CT procedure in Indolent B-cell Lymphoma

Sponsors & Collaborators

  • Koo Foundation Sun Yat-Sen Cancer Center

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-29
Primary Completion
2026-04-30
Completion
2027-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06461182 on ClinicalTrials.gov